4,087 Johnson & Johnson $JNJ Shares Bought by First Pacific Financial

First Pacific Financial raised its stake in Johnson & Johnson (NYSE:JNJ) by 18.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 26,468 shares of the company’s stock after buying an additional 4,087 shares during the period. Johnson & Johnson comprises about 0.7% of First Pacific Financial’s portfolio, making the stock its 25th biggest position. First Pacific Financial’s holdings in Johnson & Johnson were worth $7,007,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the company. Auto Owners Insurance Co boosted its position in Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after acquiring an additional 69,108,368 shares during the last quarter. Jupiter Topco LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at about $1,967,399,000. Diamant Asset Management Inc. increased its holdings in shares of Johnson & Johnson by 24,436.5% during the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock valued at $109,338,000 after acquiring an additional 4,454,778 shares in the last quarter. Corient Private Wealth LP raised its holdings in Johnson & Johnson by 127.3% during the second quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company’s stock worth $1,539,292,000 after buying an additional 3,393,981 shares during the last quarter. Finally, Wellington Management Group LLP boosted its stake in Johnson & Johnson by 12.5% during the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock valued at $5,736,851,000 after purchasing an additional 2,513,321 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ exceeded third-quarter adjusted earnings expectations, reporting EPS of $2.59 versus a $2.53 consensus, while revenue rose 5.9% year over year to $25.4 billion. Innovative Medicine was the primary growth engine, with reported 7.9% growth and strong demand for newer products. Johnson & Johnson reports Q3 2026 results and raises 2026 guidance
• Positive Sentiment: The company raised its 2026 outlook to $101.0 billion-$101.4 billion in revenue and $11.05-$11.15 in adjusted EPS. The improved forecast provides support for the stock despite the quarter’s mixed details. JNJ Q3 earnings call highlights
• Positive Sentiment: JNJ declared a quarterly dividend of $1.34 per share, equivalent to $5.36 annually and approximately a 2.2% yield, reinforcing its appeal to income-focused investors. Johnson & Johnson announces quarterly dividend

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. UBS Group set a $270.00 price objective on shares of Johnson & Johnson in a research note on Wednesday. Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday. Bank of America reissued a “neutral” rating and issued a $278.00 price target on shares of Johnson & Johnson in a research report on Tuesday, September 29th. TD Cowen increased their price objective on Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Finally, Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $273.61.

Johnson & Johnson Price Performance

JNJ opened at $253.49 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The stock’s 50 day simple moving average is $265.80 and its 200 day simple moving average is $249.47. The firm has a market cap of $610.89 billion, a price-to-earnings ratio of 38.41, a PEG ratio of 2.54 and a beta of 0.21. Johnson & Johnson has a 1 year low of $184.66 and a 1 year high of $281.07.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The firm had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same quarter in the prior year, the firm posted $2.80 earnings per share. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts predict that Johnson & Johnson will post 11.10 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is presently 62.11%.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 15,000 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at approximately $5,779,963.81. This trade represents a 50.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.